| Index | — | P/E | — | EPS (ttm) | -3.37 | Insider Own | — | Shs Outstand | 61.46M | Perf Week | 2.68% |
| Market Cap | 917.57M | Forward P/E | — | EPS next Y | -2.47 | Insider Trans | -0.13% | Shs Float | 48.09M | Perf Month | -3.74% |
| Enterprise Value | 583.57M | PEG | — | EPS next Q | -0.84 | Short Float | 15.89% | Perf Quarter | -14.93% | ||
| Income | -206.00M | P/S | — | EPS this Y | — | Short Ratio | 8.60 | Perf Half Y | -2.67% | ||
| Sales | 0.00 | P/B | 2.85 | EPS next Y | — | ROA | -56.27% | Short Interest | 7.64M | Perf YTD | 44.25% |
| Book/sh | 5.24 | P/C | 2.74 | EPS next 5Y | — | ROE | -52.89% | 52W High | 23.19 -35.62% | Perf Year | 97.49% |
| Cash/sh | 5.45 | P/FCF | — | EPS past 3/5Y | — | ROIC | -68.50% | 52W Low | 6.73 121.84% | Perf 3Y | 75.65% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — | Gross Margin | 0.00% | Volatility | 5.52% 6.14% | Perf 5Y | -31.67% |
| Dividend TTM | — | EV/Sales | — | EPS Y/Y TTM | — | Oper. Margin | 0.00% | ATR (14) | 0.94 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 8.42 | Sales Y/Y TTM | — | Profit Margin | 0.00% | RSI (14) | 44.62 | Recom | 2.00 |
| Dividend Gr. 3/5Y | — | Current Ratio | 8.42 | EPS Q/Q | 24.30% | SMA20 | 0.94% | Beta | -0.02 | Target Price | 35.00 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | — | SMA50 | -15.99% | Rel Volume | 0.81 | Prev Close | 15.03 |
| Employees | 109 | LT Debt/Eq | 0.00 | Earnings | Nov 05 | SMA200 | -5.68% | Avg Volume | 907.60K | Price | 14.93 |
| IPO Date | Jan 08, 2021 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -1.34% — | Net Debt/EBITDA | — | Volume | 730,709 | Change | -0.67% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-28-26 | Reiterated | BTIG | Buy | $40 → $41 |
| Sep-25-26 | Reiterated | HC Wainwright & Co. | Buy | $30 → $35 |
| Sep-14-26 | Reiterated | BTIG | Buy | $39 → $40 |
| Aug-17-26 | Reiterated | UBS | Buy | $30 → $27 |
| Jul-29-26 | Reiterated | BTIG | Buy | $38 → $39 |
| May-08-26 | Reiterated | Wedbush | Outperform | $36 → $37 |
| Apr-28-26 | Reiterated | HC Wainwright & Co. | Buy | $27 → $30 |
| Mar-11-26 | Reiterated | Wedbush | Outperform | $34 → $36 |
| Mar-10-26 | Reiterated | Stifel Nicolaus | $28 | |
| Feb-02-26 | Initiated | Guggenheim | Buy | $30 |
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Gross Profit | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 51 | 54 | 54 | 42 | — | — | — | — | — | |
| Research and Development | 171 | 187 | 143 | 148 | — | — | — | — | — | |
| Other Operating Expense | 0 | 1 | 0 | 1 | — | — | — | — | — | |
| Operating Income | -222 | -242 | -197 | -191 | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 18 | 22 | 29 | 22 | — | — | — | — | — | |
| Net Income Before Taxes | -206 | -220 | -167 | -169 | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | -14 | — | — | — | — | — | |
| Consolidated Net Income | -206 | -220 | -167 | -153 | — | — | — | — | — | |
| Net Income From Continuing Operations | -206 | -220 | -168 | -155 | — | — | — | — | — | |
| Net Income | -206 | -220 | -167 | -153 | — | — | — | — | — | |
| EPS (Recurring) | -3.37 | -3.72 | -3.11 | -3.69 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -3.37 | -3.72 | -3.11 | -3.69 | — | — | — | — | — | |
| EPS (Diluted) | -3.37 | -3.72 | -3.11 | -3.69 | — | — | — | — | — | |
| EBITDA | -210 | -220 | -167 | -190 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | |
| Shares Outstanding | 61 | 59 | 54 | 42 | — | — | — | — | — | |
| Market Capitalization | 911 | 611 | 658 | 428 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Michaelson Jennifer | Chief Scientific Officer | Sep 08 '26 | Option Exercise | 4.30 | 4,000 | 17,200 | 166,844 | Sep 10 |
| Michaelson Jennifer | Chief Scientific Officer | Sep 08 '26 | Sale | 21.57 | 8,000 | 172,560 | 158,844 | Sep 10 |
| Michaelson Jennifer | Chief Scientific Officer | Aug 13 '26 | Option Exercise | 4.30 | 30,000 | 129,000 | 192,844 | Aug 14 |
| Michaelson Jennifer | Chief Scientific Officer | Aug 13 '26 | Sale | 20.26 | 30,000 | 607,800 | 162,844 | Aug 14 |
| Michaelson Jennifer | Chief Scientific Officer | Jul 06 '26 | Sale | 17.82 | 8,000 | 142,560 | 162,844 | Jul 07 |
| Michaelson Jennifer | Chief Scientific Officer | Jul 06 '26 | Option Exercise | 4.30 | 4,000 | 17,200 | 170,844 | Jul 07 |
| Michaelson Jennifer | Chief Scientific Officer | May 05 '26 | Option Exercise | 4.30 | 4,000 | 17,200 | 174,844 | May 06 |
| Michaelson Jennifer | Chief Scientific Officer | May 05 '26 | Sale | 14.62 | 8,000 | 116,996 | 166,844 | May 06 |
| Michaelson Jennifer | Chief Scientific Officer | Mar 05 '26 | Option Exercise | 4.30 | 4,000 | 17,200 | 178,844 | Mar 09 |
| Michaelson Jennifer | Chief Scientific Officer | Mar 05 '26 | Sale | 15.68 | 8,000 | 125,440 | 170,844 | Mar 09 |
| Michaelson Jennifer | Chief Scientific Officer | Feb 25 '26 | Sale | 14.14 | 1,780 | 25,169 | 174,844 | Feb 26 |
| SUMER JACQUELYN L | Chief Legal Officer | Feb 24 '26 | Sale | 14.47 | 3,601 | 52,106 | 128,089 | Feb 25 |
| Michaelson Jennifer | Chief Scientific Officer | Feb 24 '26 | Sale | 14.47 | 3,601 | 52,106 | 176,624 | Feb 25 |
| AHMED NADIM | President and CEO | Feb 24 '26 | Sale | 14.47 | 13,515 | 195,562 | 390,803 | Feb 25 |
| Jones Jeffrey Alan | Chief Medical Officer | Feb 24 '26 | Sale | 14.47 | 4,582 | 66,302 | 159,968 | Feb 25 |